Albert Cha - 11 Sep 2023 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Director
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
11 Sep 2023
Net transactions value
-$54,230
Form type
4
Filing time
13 Sep 2023, 16:29:52 UTC
Previous filing
17 Oct 2022
Next filing
28 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise $40,260 +6,000 $6.71 6,000 11 Sep 2023 Direct
transaction KALV Common Stock Options Exercise $94,560 +12,000 +200% $7.88 18,000 11 Sep 2023 Direct
transaction KALV Common Stock Sale $189,050 -18,000 -100% $10.50 0 11 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (right to buy) Options Exercise $0 -6,000 -100% $0.000000* 0 11 Sep 2023 Common Stock 6,000 $6.71 Direct F2
transaction KALV Employee Stock Option (right to buy) Options Exercise $0 -12,000 -100% $0.000000* 0 11 Sep 2023 Common Stock 12,000 $7.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2 The option is fully vested.